Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
Authors:
Open Access
- 10 August 2016
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (10) , 14083-14088
Abstract
High level of serum lactate dehydrogenase (LDH) is a well-known poor prognostic factor in patients with malignancies. However, there was no data on overall survival (OS) in cancer patients with serum LDH level > 1000 IU/L, and the prognostic value of the changes in LDH over time for OS had not been reported. Clinical data of 311 cancer patients with metastatic disease with serum LDH >1000 IU/L (four times upper limit of normal) admitted consecutively to a single center were reviewed in this retrospective study. LDH level ranged from 1002 to 8235 U/L with a mean of 1689 U/L. The median OS was 1.7 months (95 % CI: 1.4–2.0). About half of patients (n = 163, 52 %) died within 2 months with the median OS of 0.5 months (95 % CI: 0.3–0.7). Only 173 patients were indicated for salvage treatment. Fifty-one patients’ serum LDH level decreased to normal at 2 months following chemotherapy; OS was significantly longer in these patients (22.6 months, 95 % CI: 10.9–34.3, p < 0.001) compared to those with persistently abnormal serum LDH at 2 months (4.0 months, 95 % CI: 3.4–4.6). The independent factors that increased the death risk were ECOG performance status 3–4 (HR: 2.05, 95 % CI: 1.42–2.97, p < 0.001), supportive care only (HR: 2.91, 95 % CI: 2.06–4.10, p < 0.001), and persistently abnormal serum LDH at 2 months (HR: 2.72, 95 % CI: 1.67–4.42, p < 0.001). In conclusion, serum LDH level > 1000 IU/L predicted a terminal stage in metastatic cancer patients. OS was significantly prolonged in patients indicated for effective palliative treatment and LDH level decreased to normal at 2 months.Keywords
This publication has 28 references indexed in Scilit:
- Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic TherapyClinical Cancer Research, 2011
- Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4BMC Cancer, 2011
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progressionProceedings of the National Academy of Sciences, 2010
- LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)European Journal of Cancer, 2009
- Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: A preliminary studyEuropean Journal of Cancer, 2007
- Serum Lactate Dehydrogenase Level is a Prognostic Factor in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with ChemoradiotherapyCancer Investigation, 2007
- Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenanceCancer Cell, 2006
- Lactate dehydrodgenase levels predict pulmonary morbidity after lung resection for non-small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2004
- Lactate: mirror and motor of tumor malignancySeminars in Radiation Oncology, 2004
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002